Verrica Pharmaceuticals Announces Positive Phase 2 Trial Results for VP-315 in Basal Cell Carcinoma at SITC 2025 Annual Meeting

Reuters

Oct 08

Verrica Pharmaceuticals Announces Positive Phase 2 Trial Results for <a href="https://laohu8.com/S/VP..UK">VP</a>-315 in Basal Cell Carcinoma at SITC 2025 Annual Meeting

Verrica Pharmaceuticals Inc. has announced that new data from its Phase 2 clinical trial of VP-315, an investigational oncolytic peptide for the treatment of basal cell carcinoma $(BCC)$, will be presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer $(SITC)$. The company will deliver both an oral presentation and a poster on the exploratory analysis of local immune activation in the tumor microenvironment 12 weeks after VP-315 treatment. The presentations are scheduled for November 5-9, 2025, at the Gaylord National Resort and Convention Center in National Harbor, Maryland. The abstract is expected to be available on the SITC website on or about November 4, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verrica Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9541533-en) on October 07, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2573936569"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573936569\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573936569?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-08 04:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573936569","market":"us","top_or_hot":-1,"title":"Verrica Pharmaceuticals Announces Positive Phase 2 Trial Results for VP-315 in Basal Cell Carcinoma at SITC 2025 Annual Meeting","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Verrica Pharmaceuticals Announces Positive Phase 2 Trial Results for <a href=\"https://laohu8.com/S/VP..UK\">VP</a>-315 in Basal Cell Carcinoma at SITC 2025 Annual Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VRCA\">Verrica Pharmaceuticals Inc.</a> has announced that new data from its Phase 2 clinical trial of VP-315, an investigational oncolytic peptide for the treatment of basal cell carcinoma <a href=\"https://laohu8.com/S/BCC\">$(BCC)$</a>, will be presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer <a href=\"https://laohu8.com/S/SITC\">$(SITC)$</a>. The company will deliver both an oral presentation and a poster on the exploratory analysis of local immune activation in the tumor microenvironment 12 weeks after VP-315 treatment. The presentations are scheduled for November 5-9, 2025, at the Gaylord National Resort and Convention Center in National Harbor, Maryland. The abstract is expected to be available on the SITC website on or about November 4, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verrica Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9541533-en) on October 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Verrica Pharmaceuticals Announces Positive Phase 2 Trial Results for VP-315 in Basal Cell Carcinoma at SITC 2025 Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVerrica Pharmaceuticals Announces Positive Phase 2 Trial Results for VP-315 in Basal Cell Carcinoma at SITC 2025 Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-08 04:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Verrica Pharmaceuticals Announces Positive Phase 2 Trial Results for <a href=\"https://laohu8.com/S/VP..UK\">VP</a>-315 in Basal Cell Carcinoma at SITC 2025 Annual Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/VRCA\">Verrica Pharmaceuticals Inc.</a> has announced that new data from its Phase 2 clinical trial of VP-315, an investigational oncolytic peptide for the treatment of basal cell carcinoma <a href=\"https://laohu8.com/S/BCC\">$(BCC)$</a>, will be presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer <a href=\"https://laohu8.com/S/SITC\">$(SITC)$</a>. The company will deliver both an oral presentation and a poster on the exploratory analysis of local immune activation in the tumor microenvironment 12 weeks after VP-315 treatment. The presentations are scheduled for November 5-9, 2025, at the Gaylord National Resort and Convention Center in National Harbor, Maryland. The abstract is expected to be available on the SITC website on or about November 4, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verrica Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9541533-en) on October 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251007:nNDL4K3frW:1","article_id":"2573936569","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573936569","pubTimestamp":1759867517,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Verrica Pharmaceuticals Announces Positive Phase 2 Trial Results for VP-315 in Basal Cell Carcinoma at SITC 2025 Annual Meeting. Verrica Pharmaceuticals Inc. has announced that new data from its Phase 2 clinical trial of VP-315, an investigational oncolytic peptide for the treatment of basal cell carcinoma , will be presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer . The company will deliver both an oral presentation and a poster on the exploratory analysis of local immune activation in the tumor microenvironment 12 weeks after VP-315 treatment. The presentations are scheduled for November 5-9, 2025, at the Gaylord National Resort and Convention Center in National Harbor, Maryland. The abstract is expected to be available on the SITC website on or about November 4, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated co","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","BK4588":"碎股","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","NDAQ":"纳斯达克OMX交易所","BK4007":"制药","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","VRCA":"Verrica Pharmaceuticals Inc."},"translate_title":"Verrica Pharmaceuticals在SITC 2025年年会上宣布VP-315治疗基底细胞癌的积极2期试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VRCA":0.9,"NDAQ":0.9},"content_text":"Verrica Pharmaceuticals Announces Positive Phase 2 Trial Results for VP-315 in Basal Cell Carcinoma at SITC 2025 Annual Meeting\n    \n\nVerrica Pharmaceuticals Inc. has announced that new data from its Phase 2 clinical trial of VP-315, an investigational oncolytic peptide for the treatment of basal cell carcinoma $(BCC)$, will be presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer $(SITC)$. The company will deliver both an oral presentation and a poster on the exploratory analysis of local immune activation in the tumor microenvironment 12 weeks after VP-315 treatment. The presentations are scheduled for November 5-9, 2025, at the Gaylord National Resort and Convention Center in National Harbor, Maryland. The abstract is expected to be available on the SITC website on or about November 4, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verrica Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9541533-en) on October 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}